Plain-English translation of NCT06810505 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a medication already approved for migraine prevention in adults, works safely and effectively in teenagers aged 12 to 17 with chronic migraines. Half of the participants will take the real medication once daily, and half will take a placebo (a pill with no medicine in it) for 12 weeks. Neither you nor your doctor will know which group you're in, which helps researchers get fair and honest results.
Chronic migraines cause significant suffering in teenagers, but this medication has only been tested and approved in adults so far. This trial will help doctors understand whether this treatment is safe and helpful for younger patients who struggle with frequent migraines.
You likely qualify if…
You likely don't qualify if…
You would take one tablet by mouth every day for 12 weeks, then be followed for 4 more weeks after that. You'll visit a clinic or hospital regularly, keep a daily diary of your headaches and symptoms, have blood tests done, and answer questionnaires about how you're feeling. The study team will check on you throughout to monitor how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States